New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots
The MOMENTUM 3 study showcases the significant survival benefits of Abbott's heart pump technology, particularly in a patient population with limited therapy options
Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease. The data are from the MOMENTUM 3 trial, the world's largest .
New Data Show Abbott s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients – Padovanews padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.